

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC

Form 8-K

November 07, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 6, 2002

TRIANGLE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	000-21589	56-1930728
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina		27707
-----	-----	-----
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code		(919) 493-5980

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

On November 6, 2002, Triangle Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits. The following document is incorporated by reference to this Report:

99.1 Press release dated November 6, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Triangle Pharmaceuticals, Inc.

(Registrant)

November 7, 2002

Date

/s/ Daniel G. Welch

(Signature)

Name: Daniel G. Welch
Title: Chairman & Chief
Executive Officer